Aberrant glycogene and glycan expression is intimately associated with carcinogenesis, invasion, and metastasis of gastric cancer (GC); however the regulatory mechanisms for glycogenes in GC cells remain unclear. Methyl-CpG-binding protein 2 (MeCP2) regulates genes by binding to methylated promoters, and in our previous work we found that it is overexpressed in GC cell lines and tissues, functioning as an oncogene. In this study we detected the expression of 212 glycogenes in MeCP2 silenced GC cells versus control using the Agilent Whole Human Genome Microarray and mining the data through bioinformatic analysis. A total of 10 glycogenes exhibited increased expression (FC ≥ 2, P < 0.05), while 16 showed decreased expression (FC ≤ 2, P < 0.05) in the MeCP2 silenced cells, which corresponded to down-regulation of Lewis antigens (UEA-I), T/Tn antigens (PNA), and mature N-glycans (PHA-E and PHA-E+L) and up-regulation of lactosylceramide, a precursor oligosaccharide of N-glycans. Examination of the TCGA Gastric Cancer databases demonstrated that nine glycogenes (24.6%) were oppositely regulated by MeCP2 in MeCP2 knockdown BGC-823 cells relative to their expression level in GC tissues, and might be downstream genes of MeCP2. Individual gene analysis suggested that neutral alpha-glucosidase AB (GANAB) knockdown can rescue the effects of MeCP2 overexpression on GC cells. MeCP2 promotes GANAB by binding to the second methylated CpG island (206 bp, −12916 to −13122) of the GANAB promoter. In conclusion, glycogenes can be either up-or down-regulated by MeCP2 directly or indirectly to alter the glycopatterning and affect the proliferation and apoptosis of GC cells.
Introduction
Gastric cancer (GC) is a frequent malignant disease, with approximately 961,000 new cases worldwide every year, and over 40% of the worldwide annual incidence occurring in China (Zhu and Li 2010; Kim et al. 2016) . Despite a global decline in the incidence and mortality over the last decade, GC remains the third leading cause of death from cancer worldwide in both sexes (Ahn and Lee 2015) . In recent years, a large aggregation of studies have found a variety of tumor-related factors such as cytokines, growth factors, and chemokines associated with the proliferation, migration, and invasion of GC cells (Hanahan and Weinberg 2011; Quail and Joyce 2013) . However, the regulatory networks involved in GC are complicated and multifactorial, indicating a critical need to identify molecular targets that hold promise for prognostic and therapeutic strategies.
Glycosylation regulates properties of proteins on the cell surface and plays an important role in biological events such as trafficking, signaling, and adhesion; influencing processes involved in development, immunity, and disease. Glycans are synthesized by glycosidases, glycosyltransferases and sulfotransferases that are encoded by glycogenes in humans. It is known that aberrant glycogene and glycan expression is intimately associated with carcinogenesis, invasion, and metastasis of GC (Pinho et al. 2013a (Pinho et al. , 2013b Wen et al. 2015) . For instance, silencing β-linked N-acetylglucosaminetransferase induces apoptosis in human GC cells through PUMA and caspase-3 pathways (Wen et al. 2015) . N-acetylglucosaminyltransferase V (GnT-V)-mediated glycosylation causes an abnormal pattern of E-cadherin expression in the gastric mucosa (Carvalho et al. 2016) . The overexpression of sialyltransferase ST3GAL4 interferes with the overall glycophenotype of GC cells, affecting a multitude of key proteins including integrins and RON receptor tyrosine kinase in malignancy (Mereiter et al. 2016) . A specific set of fucosyltranferases is associated with apomucin and Lewis antigen expression in malignant gastric epithelium compared to normal (López-Ferrer et al. 2000) . Thus, finding regulatory factors upstream of glycogenes could efficiently block signaling pathways induced by abnormal expression of glycogenes and their glycans in GC cells.
Methyl-CpG-binding protein 2 (MeCP2) is a classic methylated-DNA-binding protein that was initially recognized as a transcriptional repressor. Its functions have been expanded upon during the past decade to include acting as an activator of transcription in the nervous system (Chahrour et al. 2008) . In recent years, MeCP2 was revealed to regulate genes in vivo in myeloma , hematological malignancies (Meklat et al. 2007) , and breast (Pampalakis et al. 2009; Shin et al. 2011) , colorectal (Pancione et al. 2010) , lung (Lin et al. 2007 ), liver (Sohn et al. 2010 ) and prostate (Pulukuri et al. 2007) cancers. Our previous studies show that MeCP2 promotes cell proliferation by activating ERK1/2 and inhibiting p38 activity in human hepatocellular carcinoma HEPG2 cells (Zhao et al. 2013 ) and facilitates the growth of GC cells by suppressing miR-338-mediated antiproliferative effect (Tong et al. 2016) . In recent years, many studies have revealed that some glycogenes, such as FUT3, B4GALNT2, ST3GAL6, and B3GNT7, become hypermethylated or hypomethylated in gastrointestinal cancer cells (Serpa et al. 2006a (Serpa et al. , 2006b Kawamura et al. 2008; Lu et al. 2014) . It is unknown if there is an association between glycogenes and MeCP2, and unclear how these genes contribute to cell function in GC cells. To address these questions, we detected expression levels of 212 glycogenes in MeCP2-knockdown GC cells compared to control by using the Agilent Whole Human Genome Microarray and mined the data through bioinformatic analysis. As a model, we then explored the correlation of neutral alpha-glucosidase AB (GANAB) and MeCP2 by employing bioinformatic prediction and chromatin immunoprecipitation assay (CHIP)-PCR detection.
Results

MeCP2 functions as an oncogene in gastric cancer cells
Our previous study showed that MECP2 is overexpressed in GC cell lines and tissues, and MECP2 knockdown affects the growth of GC cells both in vitro and in vivo (Tong et al. 2016) . To demonstrate the correlation of MeCP2 and glycogenes in GC cells, MECP2 expression was silenced using RNA interference (RNAi). As shown in Figure 1A and B, mRNA and protein expression levels of MeCP2 in BGC-823 cell line were sufficiently knocked-down after transfection with siMeCP2 compared to siControl (siCtrl).
Differential expression of glycogenes in MeCP2 knockdown BGC-823 cells
Whole-genome expression measurements were obtained for BGC-823 at 48 h post-transfection with siMeCP2 and siCtrl by using a Whole Human Genome Microarray. In order to focus our analysis on specific genes of interest, we used a list of 212 glycogenes including glycotransferases, glycosidases and sulfotransferase that were involved in the synthesis or degradation of glycans (Supplementary data, Table S1 ). We first examined whether these glycogenes exhibited increased rates of expression changes as compared to all other genes, which may indicate a prominent role for glycosylation alteration in GC cells through knockdown of MeCP2. A total of 30,968 probe sets were included in this microarray and the differences in gene expression of more than 2-fold with a P-value < 0.05 was noted in 9.25 ± 0.51% (2865 ± 157) of all probe sets. Interestingly, 12.3 ± 1.8% (26 ± 4) of the 212 glycogenes transcripts changed in expression level, which was greater than the percent of differentially expressed genes in the whole probe set (9.25%). These results suggest an enrichment of transcriptional regulation of glycan biosynthesis and metabolism related genes in MeCP2 knockdown BGC-823 cells (MKBCs).
A total of 10 glycogenes exhibited increased expression (FC ≥ 2, P < 0.05), while 16 showed decreased expression (FC ≤ 2, P < 0.05) in the MKBCs compared to the control. To facilitate the comparison of changes in the glycopatterns of the MKBCs, these 26 glycogenes were classified into five categories according to their biosynthesis of glycans: (a) glycosphingolipid (GSL) biosynthesis, (b) O-Glycan biosynthesis, (c) N-Glycan biosynthesis, (d) glycosaminoglycan and glycosylphosphatidylinositol (GPI)-anchor biosynthesis, and (e) other metabolism. 30.3% of genes related to GSL-biosynthesis (33 genes), 33.3% of genes related to O-glycosylation (18 genes), 8.6% of genes related to N-glycosylation (35 genes), and 16.7% of genes related to glycosaminoglycan biosynthesis (24 genes) were altered relative to the total genes in each group. In the GSL biosynthesis, the lacto-and neolacto-series, six genes (e.g., FUT1, FUT3 and ABO) that synthesize Lewis antigens and ABO blood groups were down-regulated, while four genes (e.g., GCNT2 and UGCG) that synthesize lactosylceramide (LacCer) and GlcNAcβ1-6 branching were up-regulated in the MKBCs ( Figure 1C ). Three genes (e.g., GALNT2 and GCNT3) that synthesize mucin type O-glycans were down-regulated, while three genes (e.g., POFUT1 and POMT1) that synthesize other types of O-glycans, such as O-linked Man and Fuc types, were up-regulated in the MKBCs ( Figure 1D ). During N-glycan biosynthesis, STT3A, which catalyzes the transfer of a high mannose oligosaccharide from a lipidlinked oligosaccharide donor to an asparagine residue within an Asn-X-Ser/Thr consensus motif in nascent polypeptide chains, was upregulated; however GANAB and MAN1B1, which cleaves sequentially glucose and mannose residues from the Glc2Man9GlcNAc2 oligosaccharide precursor of immature N-glycoproteins, were down-regulated in the MKBCs ( Figure 1E ). There were four other glycogenes in glycosaminoglycan biosynthesis ( Figure 1F ) and three others in metabolism ( Figure 1G ) observed in the MKBCs.
Gene ontology analysis
To identify the major biological functions of these 26 glycogenes in GC cells, Blast2GO was used to analyze three aspects of the proteins (enzymes): molecular functions, cellular components and biological processes ( Figure 2A ). In terms of molecular functions, the carbohydrate and sugar binding properties contributed the most (17.2% and 13.8%), but other molecular functions including fucosyltransferase activity (8.6%), acetylgalactosaminyltransferase activity (8.6%) and manganese ion binding (8.6%) were also observed. For O-glycan (D) , N-glycan (E), glycosaminoglycan and glycosylphosphatidylinositol (GPI)-anchor (F), and other metabolism (G) were detected using Agilent Whole Human Genome Microarray. Differentially expressed genes were identified by the fold-change (FC) (≥ 2 of ≤ 0.5), and t tests (P < 0.05) were used for comparison to the control group. This figure is available in black and white in print and in color at Glycobiology online. the cellular components, 60.3% of proteins were intrinsic to the membrane, and 56.9% were integral to the membrane. Other proteins were located on the Golgi apparatus (36.2%), endomembrane system (25.9%) and organelle membrane (25.9%). In terms of biological processes, 29.3%, 27.6% and 24.1% of enzymes participated in glycoprotein metabolic process, glycoprotein biosynthetic process, and protein amino acid glycosylation, respectively. A GO enrichment analysis was performed to determine whether there was any difference in the three aspects of GO annotations between the upregulated and the down-regulated glycogenes in the MKBCs. The upregulated genes were mainly responsible for activation of immune response, cell adhesion, lymphocyte costimulation and positive regulation of response to stimulus. Conversely, the down-regulated genes were mainly responsible for signal transducer, cell activation, cell homeostasis, leukocyte activation, and transport ( Figure 2B ).
Expression level of mRNAs, proteins, and glycans in MeCP2 knockdown AGS cells
To validate the differential expression of these glycogenes in MeCP2 silenced GC cells, their mRNA ( Figure 3A ), protein ( Figure 3B ), and glycan levels ( Figure 3C ) were further detected in AGS cells transfected with siMeCP2 or siCtrl using real-time PCR, western blot, and lectin histochemistry, respectively. Expression levels of GANAB and FUT1 mRNAs were significantly increased while levels of UGCG and GCNT2 mRNAs were significantly decreased in the siMeCP2 transfected AGS cells. Expression of GANAB protein was decreased, while expressions of UGCG and GCNT2 proteins were increased in MeCP2 knockdown AGS cells (MKACs). In addition, expression of Fucα1-2Galβ1-4Glc(NAc) recognized by UEA-I, Galβ1-3GalNAcα-Ser/Thr(T) recognized by PNA, and bisecting GlcNAc and complex-type N-glycan recognized by PHA-E and PHA-E+L were decreased in MKACs The Cancer Genome Atlas (TCGA) provides powerful web-based resources for analysis of expression levels of target genes Examination of TCGA Gastric Cancer databases (Cancer 2014), comprising 35 normal gastric samples and 413 GC samples (Release 2016_04) , demonstrated that eight glycogenes had significantly higher expression (P ≤ 0.029), nine had significantly lower expression (P≤0.021) in GC than normal samples, and nine showed no significant difference (Table I ). Conjoint analysis with the results of the microarray, nine genes (34.6%) that were up-regulated or down-regulated in the MKBCs showed lower or higher expression in GC tissues compared to normal tissues respectively, which implies that these nine glycogenes are likely downstream genes regulated by MeCP2, acting as tumor suppressor genes or oncogenes in GC cells respectively.
GANAB is significantly overexpressed in human GC cell lines and tissues
GANAB encodes the alpha subunit of glucosidase II that plays a role in protein folding and quality control by cleaving sequentially the two innermost alpha-1,3-linked glucose residues from the Glc2Man 9GlcNAc2 oligosaccharide precursor of immature N-glycoproteins.
However, little is known about its expression level and regulation mechanism in tumor cells. In this study, GANAB was investigated as a model gene to further explore the correlation of glycogenes and MeCP2. RT-PCR was used to measure expression levels of GANAB mRNA in human GC cell lines AGS, MKN-45, BGC823, 7901 and normal gastric cell line DES-1. The expression levels of GANAB mRNA were higher in GC cell lines than the normal cell line ( Figure 4A ). Expression profiles of 22 primary advanced GC tissues and eight non cancerous gastric tissues (Hippo et al. 2002) from NCBI Gene Expression Omnibus (GEO) Database (Organism: Homo sapiens; Series: GSE2685; Published: 2005/05/22) revealed that RNA expression levels of GANAB were higher in GC tissues than noncancerous gastric tissues (Profile: GDS1210/D42041_at /GANAB) ( Figure 4B ). GANAB mRNA levels were also significantly increased (P < 0.0001) in 413 GC tissue samples compared with those in 35 normal stomach samples in the Can cer Genome Atlas (TCGA) cohort ( Figure 4C ). In addition, GANAB protein expression was also increased in GC tissues versus normal para-carcinoma tissues by use of immunohistochemistry ( Figure 4D ).
RNA interference-mediated silencing of GANAB suppresses proliferation and promotes apoptosis in GC cells
To test whether GANAB is involved in the effects of MeCP2 on GC cell proliferation and apoptosis, GANAB expression was silenced Alteration of glycan expression level in MKACs compared to control was detected using lectin histochemistry (images were obtained using a 40× objective lens). UEA-I, Ulex europaeus agglutinin I; PNA, Peanut agglutinin; PHA-E, Phaseolus vulgaris erythroagglutinin; and PHA-E+L, Phaseolus vulgaris agglutinin. This figure is available in black and white in print and in color at Glycobiology online.
using RNAi. mRNA and protein expression levels showed that GANAB was specifically knocked-down by siGANAB in BGC-823 and AGS cells at 36% ( Figure 4E ) and 45% ( Figure 4F ), respectively. Expression of bisecting GlcNAc and complex-type N-glycans recognized by PHA-E and PHA-E+L was decreased in siGANAB transfected BGC-823 cells ( Figure 4G ). As shown in Figure 4H -K, silencing of GANAB resulted in suppressed cell proliferation and increased cell apoptosis, which was in line with the effects of MeCP2 knockdown in BGC-823 and AGS cells, as shown in our previous paper (Tong et al. 2016) . To further examine the inhibitory role of siGANAB in BGC-823 and AGS cells, a colony formation assay was used after similar transient transfection. Notably, GANAB silenced cells displayed fewer and smaller colonies compared to control ( Figure 4L and M).
GANAB knockdown rescues the effects of MeCP2 overexpression on GC cells
To further demonstrate that MeCP2 promotes proliferation and suppresses apoptosis through GANAB, MeCP2 overexpression vector was cotransfected with siCtrl or siGANAB into BGC-823 cells. Expression levels of GANAB mRNA increased in MeCP2 overexpressed BGC-823 cells, but were reduced after cotransfection with siGANAB ( Figure 5A ). Compared to the control group, overexpression of MeCP2 promoted cell proliferation and repressed cell apoptosis. However, after cotransfection with siGANAB, the silencing of GANAB attenuated the effect of MeCP2 in BGC-823 cells ( Figure 5B and C) . In addition, using the cotransfection in the colony formation assay further verified that the increased MeCP2 activity was neutralized by the knockdown of GANAB in BGC-823 cells ( Figure 5D ).
MeCP2 promotes GANAB by binding the methylated CpG island of the GANAB promoter
CpG island predictions for the human GANAB promoter were made with the MethPrimer software (http://www.urogene.org/methprimer/ index1.html) and EMBOSS Cpgplot software (Source-version EMBOSS 6.6.0.0) (http://www.ebi.ac.uk/Tools/seqstats/emboss_cpgplot/) using the following parameters: island size > 200, GC% > 50.0%, and Obs/ Exp > 0.6. The ECR Browser software (http://ecrbrowser.dcode.org/) was used to predict conserved promoter regions in human GANAB. A CpG island prediction analysis in the 15 kb region upstream of the GANAB start codon revealed two CpG islands (island 1: 247 bp, −12098 to −12345; island 2: 206 bp, −12916 to −13122) in the 3' flanking sequence ( Figure 5E ). To further elucidate the potential relationship between the CpG islands on GANAB promoter and MeCP2, a ChIP assay combined with real-time PCR was performed to further validate the involvement of MeCP2 in two predicted CpG islands of the GANAB promoter. The results showed remarkable binding of MeCP2 to the second CpG island in BGC-823 cells, but no IgG recruitment was observed ( Figure 5F ). 11.44 ± 0.11, n = 35) 11.42 ± 0.03, n = 413 0.797 ns ST6GALNAC1
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Discussion
Glycans participate in major pathophysiology events during tumor progression, and altered glycosylation is a universal feature of malignancy (Stowell et al. 2015; Pinho and Reis 2015) . Human protein MeCP2 represses transcription of genes by binding specifically to the methylated DNA and recruiting the co-repressors Sin3A and histone deacetylases 1 and 2 (Zimmermann et al. 2015) . Some known glycogenes have been shown to undergo hypomethylation or hypermethylation in GC (Vojta et al. 2016 ). This study showed that in GC cells with silenced MeCP2 gene there was enrichment of 12.3% differentially expressed glycogenes against 9.25% of differentially expressed other genes, indicating that glycogenes can be considered as an important group of genes that ubiquitously change expression in cancer. Glycans are involved in fundamental molecular and cell biology processes occurring in cancer, such as cell signaling and communication, tumor cell dissociation and invasion, cell-matrix interactions, tumor angiogenesis, immune modulation, and metastasis formation (Lau et al. 2007; Zhao et al. 2008; Pinho et al. 2013a Pinho et al. , 2013b . The many roles of glycans in cancer have been highlighted by the fact that alterations in glycosylation regulate the development and progression of cancer, serving as important biomarkers and providing a set of specific targets for therapeutic intervention (Pinho and Reis 2015; Vankemmelbeke et al. 2015) . In this study, 26 glycogenes were differentially expressed and assumed as potential downstream genes regulated by MeCP2 directly or indirectly to mediate a series of signaling pathways and eventually make cells cancerous. The effect of MeCP2 knockdown on the glycol-genes expression could be a primary, secondary, tertiary, etc… effect, which should be individually studied.
GSLs are essential constituents of cell membranes and lipid rafts, which can be divided generally into three major groups: (i) the ganglio-and isoganglio-, (ii) the lacto-and neolacto-, and (iii) the globoand isoglobo-series in vertebrate animal tissues (Liang et al. 2010) . GSLs have important functions as mediators of cell adhesion and signal transduction, and the expressions of GSLs are frequently and drastically changed during development (Hakomori 2008) , differentiation (Hakomori 2010) , and carcinogenesis (Ersek et al. 2015) . In this study, UGCG that synthesizes LacCer and GCNT2 that converts linear into branched poly-N-acetyllactosaminoglycans were significantly up-regulated, while FUT1, FUT3, and ABO that synthesize Lewis antigen systems (e.g., Lea, Leb, and sialylLex) were significantly down-regulated in the MECP2 knockdown GC cells ( Figure 1C ). LacCer is a ubiquitously occurring GSL, which plays a pivotal role in the biosynthesis of complex GSLs (Astudillo et al. 2015) . Recent studies show that LacCer regulates cell adhesion and proliferation in mammalian cells (Hakomori 1983; Kakugawa et al. 2002) , and that the conversion of ceramide to LacCer critically induces cell apoptosis (Martin et al. 2006 ). GCNT2, a gene encoding glucosaminyl (N-acetyl) transferase 2, I-branching enzyme, regulates the expression of cell surface I-antigen on the O-glycan and glycolipid. A recent study revealed that all of the isoforms of GCNT2 genes showed reduced expression in primary colorectal tumor tissues compared to the corresponding normal mucosa, which can be explained by promoter DNA hypermethylation (Nakamura et al. 2015) . In this study, we also found significantly lower expression levels of GCNT2 (P < 0.001) in gastric tumor tissues than normal gastric tissues. FUT3, which is responsible for overexpression of Le(a), is highly expressed in gastric cells depending upon promoter hypomethylation (Serpa et al. 2006a (Serpa et al. , 2006b ). The down-regulation of FUT3 and FUT3/FUT5 reduces the adhesion and binding capacities of GC cells (Padró et al. 2011 ). Altered ABO glycosyltransferase activity plays a key role in carcinogenesis, mainly by affecting cell proliferation, tumor invasion, and metastatic spread (Franchini et al. 2015; Xu et al. 2016 ). It could be speculated then, that genes synthesizing complex GSLs containing Lewis antigens (i.e., "leaf" genes) might be promoted by MeCP2 to act as oncogenes, while genes completing the backbone of GSLs (i.e., "limb" genes) might be suppressed by MeCP2 to act as tumor suppressor genes in GC cells.
Despite the wide acceptance that tumor-associated carbohydrate antigens, such as T/Tn and Sialyl T/Tn antigens, are highly expressed in several human carcinomas and are associated with carcinoma aggressiveness and poor prognosis (Imai et al. 2001; Nowak et al. 2009 ), the molecular mechanisms that drive these changes are often poorly understood. In this study, genes participating in Tn (GALNT2) and Sialyl T (ST6GALNAC1) synthesis were significantly restrained by MeCP2. It is generally thought that the blood group precursors T and Tn epitopes are shielded in healthy and benigndiseased tissues but uncovered in approx. 90% of carcinomas (Springer 1997) . However, this study indicates that another explanation could be that increased expression of GALNT2, which catalyzed the initial reaction in O-linked oligosaccharide biosynthesis, transfers more N-acetyl-D-galactosamine residues to serine or threonine residues on the protein receptor in carcinoma cells.
The biosynthesis of N-linked glycans occurs in the endoplasmic reticulum (ER) and the Golgi body. After the completed precursor oligosaccharide (GlcNAc2Man9Glc3) is transferred to the nascent polypeptide by STT3A in the lumen of the ER membrane, the final three glucose residues are removed from the structure by mannosyloligosaccharide glucosidase and GANAB, which is a quality control step in the ER to monitor protein folding. Then a series of mannosidases, such as MAN1B1, remove the four mannose residues in α-1,2 linkages in the cis-Golgi. After removal of the final glucose residue, glycosyltransferases add sugar residues to the core glycan structure, giving rise to the various glycan structures (Patterson 2005; Drickamer and Taylor 2006) . These glycoproteins can then be accurately transited to the cell membrane, organelles, or extracellular matrix to perform their functions. In this study, STT3A expression was promoted while GANAB and MAN1B1 expressions were suppressed by MeCP2, which indicates that N-glycoproteins might be misfolded and excessively accumulate in the lumen of the ER (Wu et al. 2011) . The deficiency of basic proteins and severe ER stress would lead to delayed proliferation of cells and apoptotic cell death (Xu et al. 2005) .
To further elucidate the correlation of MeCP2 and glycogene expression in GC cells, GANAB expression was silenced to rescue the effects of MeCP2 overexpression. Two potential CpG islands were predicted to be upstream of the GANAB start codon, and MeCP2 can directly bind to the second CpG island, which means that MeCP2 promotes GANAB by binding the methylated CpG island of the GANAB promoter. A recent study showed that the majority of genes (~85%) appeared to be activated by MeCP2 and that MeCP2 associates with the transcriptional activator CREB1 at the promoter of an activated target but not a repressed target in the hypothalamus of mice, suggesting that MeCP2 regulates the expression of a wide range of genes in the hypothalamus and that it can function as both an activator and repressor of transcription (Chahrour et al. 2008) . It is apparent that the complete biological function of MeCP2 is not fully understood. In this study, the results demonstrate that MeCP2 can either promote or suppress glycogene expression to alter the proliferation and apoptosis of GC cells, sometimes by directly binding to the methylated CpG island of the glycogene promoters.
Materials and methods
Cell lines
Human GC cell lines BGC-823, AGS, MKN-45, and 7901 were maintained in 1640 medium (1640; PAA Laboratories GmbH) supplemented with 10% FBS (PAA Laboratories GmbH) at 37°C in 5% CO 2 . Human "normal" gastric cell line DES-1 was cultured in Dulbecco's Modified Eagle Medium (Gibco™; Thermo Fisher Scientific) at 37°C in 5% CO 2 .
Oligonucleotides, plasmid construction, and transfer
Small interfering RNA (siRNA) duplexes targeting human MeCP2 and GANAB were synthesized and purified by GenePharma (Shanghai, China). Nonspecific siRNA sequences were used as a negative control. GV141 vector containing cDNA of MECP2 was purchased from GeneChem (Shanghai Genechem Co. Shanghai, China). siRNA and plasmid were transfected by Lipofectamine 2000 (Thermo Fisher Scientific), according to manufacturer's recommendation. All oligonucleotide sequences are listed in Table II .
RNA extraction and quantitative real-time PCR
Total RNA was extracted from prepared GC cell lines with TRizol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA). cDNA was synthesized using a PrimeScript™ RT reagent kit purchased from TAKARA (Takara Biotechnology Co., Ltd, Dalian, China), according to the manufacturer's protocol. Quantitative real-time PCR (qRT-PCR) was performed with the IQ5 real-time PCR detection system, using GADPH as a control. Relative quantification of mRNA expression levels was performed using SYBR Premix Ex Taq II on an FTC-3000TM System (Funglyn Biotech Inc., Toronto, Canada), according to the manufacturer's instructions . The relative expression of genes MECP2, GANAB, GCNT2, FUT1, UGCG and B3GNT5 were calculated using the 2 −ΔΔCt method. The primers used are listed in Table II .
Western blotting
Total protein was extracted from the GC cells, separated by SDS-PAGE, and transferred onto a PVDF membrane. After blocking in 5% skim milk for 30 min, the membrane was incubated with the primary antibodies overnight at 4°C, followed by incubation with alkaline phosphatase-conjugated secondary antibodies for 1 h at room temperature. Washing with Tris-buffered saline-Tween 20 was performed after each incubation. The membranes were detected using a 5-bromo-4-chloro-3-indolyl phosphate/nitrobluetetrazolium salt substrate kit. The blots were developed with the ECL system. Rabbit polyclonal antibodies to MeCP2 and UGCG proteins were purchased from GeneTex, lnc. (San Antonio, TX). Rabbit polyclonal antibodies against GANAB, GCNT2, and GADPH proteins were purchased from ProteinTech Group, lnc. (Chicago, IL).
Expression profile microarrays and data analysis RNA integrity was examined by 1% agarose gel electrophoresis. RNA concentration was measured using a Nano-Drop ® ND-100 spectrophotometer (NanoDropTechnolo-gies Inc., USA). One microgram of total RNA from each sample was doubled and transcribed into fluorescent cRNA using the manufacturer's Agilent's Quick Amp Labeling protocol (version 5.7, Agilent Technologies). RNA samples were then incubated with the Agilent Whole Human Genome Microarray containing 30,968 probes (60-mer) (Santa Clara, CA, USA). After hybridization and washing, the microarray slides were scanned with the Axon GenePix 4000Bmicroarray Scanner (Molecular Devices, LLC, USA). Original fluorescent data was read by GenePix pro V6.0software (Molecular Devices, LLC, USA) and standardized by the Agilent GeneSpring GX v11.5.1 Software (Agilent,USA) for further analysis. Differentially expressed genes (DEGs) were identified by the value of fold-change (FC) (≥2) and t tests were used for comparison with the control group. The microarray experiments and data analysis were performed by Kangchen Biotechnology Limited Company (Shanghai, China).
To determine whether specific biological functions and pathways were differentially affected by MeCP2 knockdown in the GC cell line BGC-823, ontology analysis was performed according to the standard procedure of Blast2GO (Conesa et al. 2005) to gain insights into functional groupings within the set of DEGs in three aspects of GO. The differences in the GO terms of DEGs in BGC-823 with and without MeCP2silencing were also determined through analysis using WEGO (Ye et al. 2006) . Biological pathways that were enriched in the DEGs originated from the KEGG human pathway database (Kanehisa et al. 2012) . To validate the results of Blast2GO and KEGG, an independent functional enrichment analysis was performed using DAVID (Database for Annotation, Visualization and Integrated Discovery) (Huang et al. 2009 ).
Lectin fluorescence histochemistry
Lectins labeled by Cy3 fluorescent dye were applied to detect the specific sugar structure presented in the cells according to the protocol described previously (Qin et al. 2012) . Briefly, the transfected cells were fixed and permeabilized, then blocked with 4% BSA in 1 × PBS at 37°C for 30 min. The cells were incubated with Cy3-labeled lectin diluted at a final concentration of 15-20 μg/mL in the blocking buffer for 3 h at room temperature in the dark. They were then further stained with 1 μg/mL of DAPI (Roche, Basel, CH) in 1 × PBS. Laser scanning confocal microscope FV 1000 (Olympus, Tokyo, JPN) was used to collect the images with the combination of the Cy3 and DAPI channels.
Cell proliferation assays
Gastric cancer BGC-823 and SGC-7901 cells were seeded into 96-well plates at 3000 cells/well in 200 μL/well culture medium. Cell proliferation assays were performed at 24, 48 and 72 h post-transfection according to the maufacturer's protocol for cell counting Kit-8 (CCK8) (7Sea Biotech, Shanghai, China). Absorbance was measured at a wavelength of 450 nm with FLUOstar OPTIMA (BMG). Each assay was repeated in triplicate.
Colony forming assays
Cells were seeded at a density of 500 cells/well into six-well plates, and transfected with siRNA or vectors. The cells were incubated for 14 days at 37˚C in a humidified incubator with 5% CO 2 , and subsequently stained with a crystal violet solution (Sigma-Aldrich), and imaged with a GelDoc 2000 system and Quantity One software (version 4.3.1; Bio-Rad Laboratories, Inc., Hercules, CA, USA). 
Cell apoptosis assays
Cell apoptosis analysis was assessed using an Annexin-VFITC Apoptosis Detection Kit (7Sea Biotech, Shanghai, China), according to the manufacturer's instructions. After transfection, cells were cultured at 37°C for 24 h. The cells were then stained using 5 μL of FITC Annexin V and 5 μL PI. The apoptosis of cells as a percentage was measured using a flow cytometer (Becton-Dickinson) and analyzed by ModFite software.
Statistical analysis
All statistical analyses were performed using SPSSS statistics 13.0 (SPSS, Chicago, IL, USA). Data were presented as mean ± SEM of at least three independent experiments and statistical significance of the differences between groups was calculated using the Student t-test. All tests were two-sided and P < 0.05 was considered as statistically significant.
Chromatin immunoprecipitation assay
CHIP was performed according to the methods described previously . Briefly, BGC-823 cells were pretreated, crosslinked, and sheared through ultrasonication. The sheared chromatin was immunoprecipitated with anti-MeCP2 or IgG antibody (Abcam) overnight at 4°C. The DNA was purified from the immunocomplexes and used as a template for the ChIP-PCR assay. The primers for quantitative real-time PCR are listed in Table II .
Supplementary data
Supplementary data are available at Glycobiology online.
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